Millions of individuals 65 years of age and older fall each year, leading to direct medical costs of approximately $34 billion per year in the US alone (Stevens et al., 2006). Cognitive decline has often been used as an exclusion criterion in studies regarding falls, although changes in cognitive processing are now thought to increase the risk of falls (Domingos et al., 2015). Older adults tend to have more difficulty dividing attention among multiple tasks (Verhaeghen & Cerella, 2002). Thus, challenges to the limits of attentional processing, such as distracting stimuli, may limit the ability to attend and make adjustments in order to maintain balance, thereby increasing the likelihood of falls. More recent experiments have focused on attentional deficits in conditions such as Parkinson's disease, associated with motor deficits and increased risk of falls (Pelosin et al., 2016). This mounting evidence leads to the conclusion that drug treatments that facilitate attentional processing may decrease the risk of falls.A next step in this area is to identify relevant underlying mechanisms involved in motor control and attention, assess changes in the brain regions in relevant conditions such as Parkinson's disease and then evaluate whether treatments that facilitate attentional processing can decrease the rate of falls. Dopamine release within the dorsal striatum has long been associated with various aspects of motor control, including initiating and stopping movements, and degeneration of dopaminergic pathways from the substantia nigra to the striatum is well-established in Parkinson's disease. Several neurotransmitter systems have been implicated in attention, with strong evidence indicating that basal forebrain corticopetal cholinergic neurons are necessary for attention (Klinkenberg et al., 2011). Kucinski et al. (2013) established a model whereby lesions of dopaminergic terminals in the dorsal striatum along with lesions of basal forebrain corticopetal cholinergic neurons increased the rate of falls by rats in a motor task that varied demands to maintain balance and included presentation of distracting stimuli. Importantly, other studies in humans also provide evidence that dysfunctional cholinergic activity contributes to an increase in falls in patients with Parkinson's disease and in the elderly, supporting the translational potential of the animal model (Pelosin et al., 2016). The next step, described in the paper in this issue by Kucinski et al., is to test whether treatments that target depressed cortical cholinergic function attenuate the increased fall rate in this animal model. Acetylcholinesterase (AChE) inhibitors, such as donepezil, have been used with some success to restore cholinergic deficiency and improve cognitive function in patients with Alzheimer's disease. However, given the limited benefits of AChE inhibitors, clearly other treatments are needed to improve disrupted cognitive processes, including attention. In the present manuscript, the effects of co-administering donepezil with the 5-HT...